PTC Therapeutics, Inc. (PTCT) on GreekSoup https://greeksoup.ai/stocks/us/ptct/ Every dated entry in the public record on PTC Therapeutics, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Mon, 12 Oct 2026 00:00:00 +0000 PTC Therapeutics, Inc.: Form 144, Boulding Mark Elliott plans to sell 192 shares worth $12,339 around 9 October 2026https://greeksoup.ai/stocks/us/ptct/planned-sales/us:PTCT:planned-sale:2026-10-09:75406fa568Fri, 09 Oct 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 2,447 shares at $63.38 on 7 October 2026, $155,091https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-10-09:b546305790Fri, 09 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 53 shares at $63.95 on 7 October 2026, $3,389https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-10-09:3cb91125e7Fri, 09 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Form 144, Section Six Partners, L.P. plans to sell 10,000 shares worth $643,500 around 7 October 2026https://greeksoup.ai/stocks/us/ptct/planned-sales/us:PTCT:planned-sale:2026-10-07:64e7fa57d8Wed, 07 Oct 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Boulding Mark Elliott (EXEC. VP AND CLO) sold 435 shares at $64.16 on 6 October 2026, $27,910https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-10-07:e0cdb593e5Wed, 07 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Boulding Mark Elliott (EXEC. VP AND CLO) sold 1,638 shares at $64.03 on 5 October 2026, $104,881https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-10-07:ebc1686a79Wed, 07 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Form 144, Boulding Mark Elliott plans to sell 435 shares worth $27,908 around 6 October 2026https://greeksoup.ai/stocks/us/ptct/planned-sales/us:PTCT:planned-sale:2026-10-06:1a0869a8c4Tue, 06 Oct 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Form 144, Boulding Mark Elliott plans to sell 1,638 shares worth $104,883 around 5 October 2026https://greeksoup.ai/stocks/us/ptct/planned-sales/us:PTCT:planned-sale:2026-10-05:18ccf1fe78Mon, 05 Oct 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Steele Glenn Jr Md Phd (Director) sold 12,000 shares at $65.16 on 30 September 2026, $781,920https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-10-02:487c94b9fbFri, 02 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Form 144, STEELE GLENN JR MD PHD plans to sell 12,000 shares worth $781,920 around 30 September 2026https://greeksoup.ai/stocks/us/ptct/planned-sales/us:PTCT:planned-sale:2026-09-30:6f49666a0cWed, 30 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: short interest 9,168,333 shares at the 30 September 2026 settlement, 6.14 days to coverhttps://greeksoup.ai/stocks/us/ptct/short-interest/us:PTCT:short-interest:2026-09-30:c2e7cbd406Wed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc. filed 8-K: regulation fd disclosure, other eventshttps://greeksoup.ai/stocks/us/ptct/filings/us:PTCT:filing:2026-09-21:8ed84e8fa4Mon, 21 Sep 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 9,624 shares at $67.83 on 17 September 2026, $652,796https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-09-18:1f46eed271Fri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 376 shares at $68.45 on 17 September 2026, $25,737https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-09-18:a6968a6ac7Fri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 2,994 shares at $66.58 on 16 September 2026, $199,341https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-09-18:eab20dd66dFri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 7,006 shares at $67.35 on 16 September 2026, $471,854https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-09-18:ad5926b86dFri, 18 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: short interest 9,738,919 shares at the 15 September 2026 settlement, 11.03 days to coverhttps://greeksoup.ai/stocks/us/ptct/short-interest/us:PTCT:short-interest:2026-09-15:1a00c76a77Tue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 10,000 shares at $67.34 on 10 September 2026, $673,400https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-09-11:60e3e30735Fri, 11 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 9,428 shares at $67.79 on 9 September 2026, $639,124https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-09-11:8a404cc93bFri, 11 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 572 shares at $68.67 on 9 September 2026, $39,279https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-09-11:828bf52633Fri, 11 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Form 144, Section Six Partners, L.P. plans to sell 40,000 shares worth $2.7 million around 9 September 2026https://greeksoup.ai/stocks/us/ptct/planned-sales/us:PTCT:planned-sale:2026-09-09:0153488bbbWed, 09 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: short interest 9,828,154 shares at the 31 August 2026 settlement, 12.13 days to coverhttps://greeksoup.ai/stocks/us/ptct/short-interest/us:PTCT:short-interest:2026-08-31:1d0041fea1Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc. filed 8-K: material agreementhttps://greeksoup.ai/stocks/us/ptct/filings/us:PTCT:filing:2026-08-28:1742af6c11Fri, 28 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 11,890 shares at $71.55 on 27 August 2026, $850,730https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-28:b6d7d089f7Fri, 28 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 610 shares at $72.22 on 27 August 2026, $44,054https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-28:901e834bf7Fri, 28 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 6,874 shares at $72.74 on 26 August 2026, $500,015https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-28:5458adac23Fri, 28 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 5,626 shares at $73.18 on 26 August 2026, $411,711https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-28:feab5f8912Fri, 28 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 9,419 shares at $70.78 on 20 August 2026, $666,677https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-21:aca080323aFri, 21 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 2,390 shares at $71.88 on 20 August 2026, $171,793https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-21:b2fc7790acFri, 21 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 691 shares at $72.92 on 20 August 2026, $50,388https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-21:156a489c64Fri, 21 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 5,335 shares at $72.86 on 19 August 2026, $388,708https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-21:c58c803398Fri, 21 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Schmertzler Michael (Director) sold 7,165 shares at $73.67 on 19 August 2026, $527,846https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-21:0b9569a500Fri, 21 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Form 144, Michael Schmertzler plans to sell 50,000 shares worth $3.6 million around 19 August 2026https://greeksoup.ai/stocks/us/ptct/planned-sales/us:PTCT:planned-sale:2026-08-19:7724f1d01fWed, 19 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Boulding Mark Elliott (EXEC. VP AND CLO) sold 1,844 shares at $72.39 on 17 August 2026, $133,487https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-19:f2092ac73cWed, 19 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Boulding Mark Elliott (EXEC. VP AND CLO) sold 969 shares at $72.90 on 17 August 2026, $70,640https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-19:8d7becc4e0Wed, 19 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Form 144, Boulding Mark Elliott plans to sell 2,813 shares worth $201,692 around 17 August 2026https://greeksoup.ai/stocks/us/ptct/planned-sales/us:PTCT:planned-sale:2026-08-17:958d94e63eMon, 17 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: short interest 10,221,046 shares at the 14 August 2026 settlement, 10.82 days to coverhttps://greeksoup.ai/stocks/us/ptct/short-interest/us:PTCT:short-interest:2026-08-14:5a55c8c5a9Fri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc. filed 8-K: regulation fd disclosure, other eventshttps://greeksoup.ai/stocks/us/ptct/filings/us:PTCT:filing:2026-08-13:a732625458Thu, 13 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Klein Matthew B. (CHIEF EXECUTIVE OFFICER) sold 10,292 shares at $68.57 on 4 August 2026, $705,722https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-08-06:ab1dec34abThu, 06 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Form 144, Klein Matthew B. plans to sell 10,292 shares worth $705,754 around 4 August 2026https://greeksoup.ai/stocks/us/ptct/planned-sales/us:PTCT:planned-sale:2026-08-04:f795b160d1Tue, 04 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: short interest 10,566,249 shares at the 31 July 2026 settlement, 7.52 days to coverhttps://greeksoup.ai/stocks/us/ptct/short-interest/us:PTCT:short-interest:2026-07-31:9bebc985ddFri, 31 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc. Q2 FY2026 results: revenue $361 million, net income $83 millionhttps://greeksoup.ai/stocks/us/ptct/results/fy2026-q2/us:PTCT:result:2026-07-30:ed64def63cThu, 30 Jul 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/ptct/filings/us:PTCT:filing:2026-07-30:ff935ef14cThu, 30 Jul 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc. filed 8-K: results of operations, officer or director change, regulation fd disclosurehttps://greeksoup.ai/stocks/us/ptct/filings/us:PTCT:filing:2026-07-30:8fdcafa68bThu, 30 Jul 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Gravier Pierre (CHIEF FINANCIAL OFFICER) sold 3,494 shares at $80.35 on 14 July 2026, $280,743https://greeksoup.ai/stocks/us/ptct/insiders/us:PTCT:insider:2026-07-16:d72fab911eThu, 16 Jul 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: short interest 9,833,980 shares at the 15 July 2026 settlement, 4.75 days to coverhttps://greeksoup.ai/stocks/us/ptct/short-interest/us:PTCT:short-interest:2026-07-15:87a6bf3badWed, 15 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> PTC Therapeutics, Inc.: Form 144, Gravier Pierre plans to sell 3,494 shares worth $280,733 around 14 July 2026https://greeksoup.ai/stocks/us/ptct/planned-sales/us:PTCT:planned-sale:2026-07-14:bd03c8eb8fTue, 14 Jul 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]>